This site is intended only for healthcare professionals resident in India
Menu
Close
ZINFORO®: Bactericidal activity against resistant isolates with high binding affinity in Streptococcus pneumoniae1-3,*
The available clinical data cannot substantiate efficacy against penicillin-resistant strains of S. pneumoniae. Caution is advised when treating such patients. ZINFORO® is not indicated for MRSA in CAP – the comparator in the clinical studies, ceftriaxone, is not active against MRSA.5
ZINFORO® exerts potent bactericidal activity in cSSTI against resistant isolates with high binding affinity to mutated beta-lactam-binding proteins.1-4,6,7
It achieves bactericidal activity in CAP against resistant isolates with high binding affinity in S. pneumoniae.1-3
ZINFORO® (ceftaroline fosamil) has relatively low protein binding affinity (<20%) and would be predicted to attain rapid penetration to the primary infection site.3
ZINFORO® (ceftaroline fosamil) penetrates the bronchial ELF of healthy subjects, with a penetration relative to that of plasma of 23%.8
At a dose of 600 mg every 12 hours and an MIC of 1 mg/L:
*Recommended for patients without risk factors for MRSA or Pseudomonas aeruginosa.9
ATS, American Thoracic Society; CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infection; ELF, epithelial lining fluid; IDSA, Infectious Diseases Society of America; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; PBP2x, penicillin-binding protein 2x; PBP, penicillin-binding protein; PD, pharmacodynamics; PK, pharmacokinetics; q8h, every 8 hours; q12h, every 12 hours.
References:
Example
Example
Proven clinical efficacy in patients with
CAP and cSSTI
ZINFORO® in the treatment of CAP and cSSTI
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.